News | March 06, 2025
Zydus Lifesciences launches ANVIMO
ANVIMO will be available in dosages of 240 mg and 480 mg
ANVIMO will be available in dosages of 240 mg and 480 mg
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
No safety signals related to the vaccine candidate were identified
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Subscribe To Our Newsletter & Stay Updated
